Cited by 940Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Egen, Jackson G., Kuhns, Michael S., Allison, James P.·2002·Nature Immunology

Open this paper in CoChat — free account

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Integrity signals

Registry

Crossref · 10.1038/ni0702-611

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
Dranoff, G., Jaffee, E. M., Lazenby, A., Golumbek, P. T., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. M., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,822
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
The B7–CD28 superfamily
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759

Show all 93 references

Sorted by citations

Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citation
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Self-citation
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
“Proposed mechanisms for such inhibitory signals include direct inhibition at the TCR immune synapse, inhibition of CD28 or its signaling pathway, or increased mobility of T cells leading to decreased ability to interact with APCs.(9,12,13) CTLA-4 itself is subject to regulation, particularly by localization within the…”
Background
The B7 family revisited
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,612
The Genetic Structure and History of Africans and African Americans
Tishkoff, S. A., Reed, F. A., Friedlaender, F. R., Ehret, C., Ranciaro, A., Froment, A., Hirbo, J. B., Awomoyi, A. A., Bodo, J.-M., Doumbo, O., et al. (2009) · Science · doi:10.1126/science.1172257 · Cited by 1,573
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,272
Alcohol, oxidative stress and free radical damage
Albano, E. (2006) · Proceedings of The Nutrition Society · doi:10.1079/pns2006496 · Cited by 1,223
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,249
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu‐Nosjean, M., Tartour, É., Sautès‐Fridman, C., & Fridman, W. H. (2009) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,126
Immune-Mediated Inhibition of Metastases after Treatment with Local Radiation and CTLA-4 Blockade in a Mouse Model of Breast Cancer
Demaria, S., Kawashima, N., Yang, A. M., Devitt, M. L., Babb, J. S., Allison, J. P., & Formenti, S. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.728.11.2 · Cited by 1,027
Self-citation
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system
Stumhofer, J. S., Laurence, A., Wilson, E. H., Huang, E., Tato, C. M., Johnson, L. M., Villarino, A. V., Huang, Q., Yoshimura, A., Sehy, D., et al. (2006) · Nature Immunology · doi:10.1038/ni1376 · Cited by 955
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
Defective Suppressor Function in CD4+CD25+ T-Cells From Patients With Type 1 Diabetes
Sm, L., Dayan, C. M., Bishop, A. J., Roep, B. O., Peakman, M., & Tree, T. I. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.92 · Cited by 881
African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease Mapping
Campbell, M. C., & Tishkoff, S. A. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164258 · Cited by 879
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
“We and many others have shown that the main targets of negative regulators of T-cell activation are cell growth and metabolism (13, 15, 39, 83).”
Background
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 738
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700
T-cell-antigen recognition and the immunological synapse
Huppa, J. B., & Davis, M. M. (2003) · Nature reviews. Immunology · doi:10.1038/nri1245 · Cited by 683
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature reviews. Immunology · doi:10.1038/nri1150 · Cited by 631
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Reversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A. M., Zinselmeyer, B. H., Rush, C. M., Brewer, J. M., Wei, B. K., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 617
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 626
Maintaining the norm: T-cell homeostasis
Jameson, S. C. (2002) · Nature reviews. Immunology · doi:10.1038/nri853 · Cited by 597
Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 551
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
Kaufmann, D., Kavanagh, D. G., Pereyra, F., Zaunders, J., Mackey, E. W., Miura, T., Palmer, S., Brockman, M. A., Rathod, A., Trocha, A. K., et al. (2007) · Nature Immunology · doi:10.1038/ni1515 · Cited by 523
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D., Wu, X., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 538
Malignant melanoma: genetics and therapeutics in the genomic eraPreprint
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 524
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Marshall, N. A., Christie, L. E., Munro, L., Culligan, D. J., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2003) · Blood · doi:10.1182/blood-2003-07-2594 · Cited by 506
Implications of biogeography of human populations for 'race' and medicine
Tishkoff, S. A., & Kídd, K. K. (2004) · Nature Genetics · doi:10.1038/ng1438 · Cited by 514
Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade
Zhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Ma, Y., Wang, S., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805888 · Cited by 503
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Fackenthal, J. D., & Olopade, O. I. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2054 · Cited by 497
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & SUKOR, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 470
See no evil, hear no evil, do no evil: the lessons of immune privilege
Niederkorn, J. Y. (2006) · Nature Immunology · doi:10.1038/ni1328 · Cited by 459
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Chae, Y. K., Arya, A., Iams, W. T., Cruz, M. R. D. S., Chandra, S., Choi, J., & Giles, F. J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0349-3 · Cited by 457
The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T Cells
Amarnath, S., Mangus, C. W., Wang, J. C. M., Wei, F., He, A., Kapoor, V., Foley, J., Massey, P. R., Felizardo, T. C., Riley, J. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003130 · Cited by 463
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 448
Self-citation
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva‐Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 446
Self-citation
Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434
In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity
den Brok, M. H., Sutmuller, R. P. M., van der Voort, R., Bennink, E. J., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3949 · Cited by 429
T‐cell exhaustion in HIV infection
Fenwick, C. W., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., & Pantaleo, G. (2019) · Immunological Reviews · doi:10.1111/imr.12823 · Cited by 429
Human T Regulatory Cell Therapy: Take a Billion or So and Call Me in the Morning
Riley, J. L., June, C. H., & Blazar, B. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.006 · Cited by 415
Cervical Cancer Immunotherapy: Facts and Hopes
Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C., & Wu, T. ‐. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2833 · Cited by 414
B7x: A widely expressed B7 family member that inhibits T cell activation
Zang, X., Loke, P., Kim, J., MURPHY, K. M. M., Waitz, R., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434299100 · Cited by 403
Self-citation
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 401
Continuous T cell receptor signaling required for synapse maintenance and full effector potential
Huppa, J. B., Gleimer, M., Sumen, C., & Davis, M. M. (2003) · Nature Immunology · doi:10.1038/ni951 · Cited by 393
Regulatory T Cells in Cancer
Mougiakakos, D., Choudhury, A., Lladser, Á., Kiessling, R. W., & Johansson, C. C. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07003-x · Cited by 413
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Galustian, C., Meyer, B., Labarthe, M., Dredge, K. S., Klaschka, D., Henry, J. Y., Todryk, S. M., Chen, R., Muller, G. W., Stirling, D., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0620-4 · Cited by 395
Patterns of Human Genetic Diversity: Implications for Human Evolutionary History and Disease
Tishkoff, S. A., & Verrelli, B. C. (2003) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.4.070802.110226 · Cited by 396
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Thomas, R., Al‐Khadairi, G., Roelands, J. P., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00947 · Cited by 388
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
Duan, F., Duitama, J., Seesi, S. A., Ayres, C. M., Corcelli, S. A., Pawashe, A., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 383
Combining radiotherapy and immunotherapy: A revived partnership
Demaria, S., Bhardwaj, N., McBride, W. H., & Formenti, S. C. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.06.032 · Cited by 376
Proportionally more deleterious genetic variation in European than in African populations
Lohmueller, K. E., Indap, A. R., Schmidt, S., Boyko, A. R., Hernandez, R. D., Hubisz, M. J., Sninsky, J. J., White, T. J., Sunyaev, S. R., Nielsen, R., et al. (2008) · Nature · doi:10.1038/nature06611 · Cited by 372
Nutritional genomics: the next frontier in the postgenomic era
Kaput, J., & Rodriguez, R. L. (2004) · Physiological Genomics · doi:10.1152/physiolgenomics.00107.2003 · Cited by 364
Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci
Zhernakova, A., Stahl, E. A., Trynka, G., Raychaudhuri, S., Festen, E. A. M., Franke, L., Westra, H.-J., Fehrmann, R. S. N., Kurreeman, F. A. S., Thomson, B. P., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002004 · Cited by 362
Recent Progresses in Phototherapy‐Synergized Cancer Immunotherapy
Ng, C. W., Li, J., & Pu, K. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804688 · Cited by 353
Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 342
Tumor infiltrating lymphocytes in ovarian cancer
Santoiemma, P. P., & Powell, D. J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040960 · Cited by 349
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 340
Self-citation
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)
Workman, C. J., & Vignali, D. A. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.688 · Cited by 344
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 327
Cancer immunotherapy with mRNA‐transfected dendritic cells
Gilboa, E., & Vieweg, J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00139.x · Cited by 314
The New Era in Cancer Research
VARMUS, H. E. (2006) · Science · doi:10.1126/science.1126758 · Cited by 315
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
Sobhani, N., Tardiel-Cyril, D. R., Davtyan, A., Generali, D., Roudi, R., & Li, Y. (2021) · Cancers · doi:10.3390/cancers13061440 · Cited by 317
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 312
Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence
Camus, M., Tosolini, M., Mlecnik, B., Pagès, F., Kirilovsky, A., Berger, A., Costes, A., Bindea, G., Charoentong, P., Bruneval, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2654 · Cited by 323
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
Orabona, C., Grohmann, U., Belladonna, M. L., Fallarino, F., Vacca, C., Bianchi, R., Bozza, S., Volpi, C., Salomon, B. L., Fioretti, M. C., et al. (2004) · Nature Immunology · doi:10.1038/ni1124 · Cited by 305
CTLA-4: From mechanism to autoimmune therapy
Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106221 · Cited by 308
Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Frielink, C., Toonen, L. W. J., Boerman, O. C., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603341 · Cited by 302
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
Weber, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 284
A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance
Terabe, M., Swann, J. B., Ambrosino, E., Sinha, P., Takaku, S., Hayakawa, Y., Godfrey, D. I., Ostrand‐Rosenberg, S., Smyth, M. J., & Berzofsky, J. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051381 · Cited by 283
Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses
Bennett, F., Luxenberg, D. P., Ling, V., Wang, I., Marquette, K., Lowe, D., Khan, N., Veldman, G. M., Jacobs, K. A., Valge-Archer, V., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.711 · Cited by 291
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 287
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) participates in the negative regulation of T cell activation and proliferation, which suppresses anti-tumor response [91].”
Background
T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival
Boorjian, S. A., Sheinin, Y. M., Crispen, P. L., Farmer, S. A., Lohse, C. M., Kuntz, S. M., Leibovich, B. C., Kwon, E. D., & Frank, I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0731 · Cited by 270
Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence
Zhang, B., Beeghly-Fadiel, A. C., Long, J., & Zheng, W. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70076-6 · Cited by 276
The promise of cancer vaccines
Gilboa, E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1359 · Cited by 268
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Self-citation
Progress on new vaccine strategies for the immunotherapy and prevention of cancer
Berzofsky, J. A., Terabe, M., Oh, S., Belyakov, I. M., Ahlers, J. D., Janik, J. E., & Morris, J. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21926 · Cited by 259
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 262
Neural and Immunological Synaptic Relations
Dustin, M. L., & Colman, D. (2002) · Science · doi:10.1126/science.1076386 · Cited by 256
The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling
Staudt, L. M., & Davé, S. S. (2005) · Advances in immunology · doi:10.1016/s0065-2776(05)87005-1 · Cited by 262
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Wolchok, J. D., & Saenger, Y. M. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 255
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Fong, L. H., Kwek, S. S., O’Brien, S., Kavanagh, B., McNeel, D. G., WEINBERG, V. K., Lin, A., Rosenberg, J. E., Ryan, C. J., Rini, B. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3529 · Cited by 245
Inhibitory Receptors Beyond T Cell Exhaustion
Marraco, S. A. F., Neubert, N. J., Verdeil, G., & Speiser, D. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00310 · Cited by 250

Authors: Egen, J. G., Kuhns, M. S., & Allison, J. P.
Affiliations: Howard Hughes Medical Institute (US)
Corresponding author: Allison, James P.
ORCID: Egen, Jackson G.
Kuhns, Michael S.
Allison, James P.
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2002-07
Volume: 3
Issue: 7
Pages: 611-618
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni0702-611
OpenAlex: W2140460887
Cited by: 940
References: 93
Citations by year: 2026: 10 · 2025: 15 · 2024: 30 · 2023: 34 · 2022: 45 · 2021: 50 · 2020: 43 · 2019: 33 · 2018: 27 · 2017: 36 · 2016: 28 · 2015: 32 · 2014: 31 · 2013: 38 · 2012: 25
FWCI: 5.88
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health
National Cancer Institute (CA40041, R01CA057986, CA57986)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, costimulatory receptors, CD28, T cell activation, T cell receptor signaling, T cell regulation, cancer immunotherapy, CTLA-4 blockade, immune checkpoint blockade
MeSH terms: Abatacept, Animals, Antigens, Differentiation, Cell Division, Colonic Neoplasms, Disease Models, Animal, Fibrosarcoma, Gene Expression Regulation, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antigens, CD, Immunoconjugates, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CTLA-4: new insights into its biological function and use in tumor immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks